Recurrent Melanoma Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02298959Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid TumorsTreatment
NCT02595866Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant NeoplasmsTreatment